NCT01986088View on ClinicalTrials.gov

Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,008

Participants

Timeline

Start Date

November 30, 1996

Primary Completion Date

January 31, 1998

Study Completion Date

January 31, 1998

Conditions
Migraine With or Without Aura
Interventions
DRUG

Placebo

matching placebo

DRUG

Eletriptan 40 mg

40mg oral

DRUG

Eletriptan 80 mg

80mg oral

DRUG

Sumatriptan 50 mg

50mg oral

DRUG

Sumatriptan 100 mg

100mg oral

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01986088 - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study | Biotech Hunter | Biotech Hunter